X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PD-001 (cepharanthine) is an approved, oral, small molecule natural product candidate. It is being evaluated for the treatment of cancer and covid-19 infection.
Lead Product(s): Cepharanthine
Therapeutic Area: Oncology Product Name: PD-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
Sairiyo will use the net proceeds to advance developments of cepharanthine, for cancer and infectious diseases, and DMT PharmaPatch (N,N-dimethyltryptamine) as a potential treatment for ocular disease and neuropsychiatric conditions.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: PharmaPatch
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaTher
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Financing July 18, 2023
Details:
Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases.
Lead Product(s): Cepharanthine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pharmadrug Production GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 25, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
